JP2014521609A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521609A5
JP2014521609A5 JP2014521885A JP2014521885A JP2014521609A5 JP 2014521609 A5 JP2014521609 A5 JP 2014521609A5 JP 2014521885 A JP2014521885 A JP 2014521885A JP 2014521885 A JP2014521885 A JP 2014521885A JP 2014521609 A5 JP2014521609 A5 JP 2014521609A5
Authority
JP
Japan
Prior art keywords
ring
group
membered
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014521885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521609A (ja
JP6062432B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/000709 external-priority patent/WO2013013308A1/en
Publication of JP2014521609A publication Critical patent/JP2014521609A/ja
Publication of JP2014521609A5 publication Critical patent/JP2014521609A5/ja
Application granted granted Critical
Publication of JP6062432B2 publication Critical patent/JP6062432B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014521885A 2011-07-27 2012-07-26 プロテインキナーゼ阻害薬用スピロ環状分子 Expired - Fee Related JP6062432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161457980P 2011-07-27 2011-07-27
US61/457,980 2011-07-27
PCT/CA2012/000709 WO2013013308A1 (en) 2011-07-27 2012-07-26 Spirocyclic molecules as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2014521609A JP2014521609A (ja) 2014-08-28
JP2014521609A5 true JP2014521609A5 (cg-RX-API-DMAC7.html) 2015-09-10
JP6062432B2 JP6062432B2 (ja) 2017-01-18

Family

ID=47600420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521885A Expired - Fee Related JP6062432B2 (ja) 2011-07-27 2012-07-26 プロテインキナーゼ阻害薬用スピロ環状分子

Country Status (6)

Country Link
US (1) US9226923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739617A4 (cg-RX-API-DMAC7.html)
JP (1) JP6062432B2 (cg-RX-API-DMAC7.html)
CN (1) CN103732588B (cg-RX-API-DMAC7.html)
CA (1) CA2842841C (cg-RX-API-DMAC7.html)
WO (1) WO2013013308A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6546596B2 (ja) * 2013-09-26 2019-07-17 カデント セラピューティクス,インコーポレーテッド Nr2bの選択的オクタヒドロ−シクロペンタ[c]ピロール負調節因子
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CR20220141A (es) 2019-10-09 2022-05-03 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
KR102798432B1 (ko) 2019-10-09 2025-04-22 노파르티스 아게 M4 작용제로서의 5-옥사-2-아자스피로[3.4]옥탄 유도체
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
ES2401330T3 (es) * 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2336625T3 (es) * 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
MX2010004491A (es) * 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2−アミノピリジン系キナーゼ阻害薬
BRPI1010974A2 (pt) * 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
CN101851237B (zh) * 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use

Similar Documents

Publication Publication Date Title
JP2014521609A5 (cg-RX-API-DMAC7.html)
JP2011511095A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2014520898A5 (cg-RX-API-DMAC7.html)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2010523670A5 (cg-RX-API-DMAC7.html)
JP2013535491A5 (cg-RX-API-DMAC7.html)
JP2013522292A5 (cg-RX-API-DMAC7.html)
JP2012531433A5 (cg-RX-API-DMAC7.html)
JP2015517574A5 (cg-RX-API-DMAC7.html)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
RU2012112824A (ru) Производные бис-бензимидазола
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2016503799A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP2013544261A5 (cg-RX-API-DMAC7.html)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2008528467A5 (cg-RX-API-DMAC7.html)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2016506958A5 (cg-RX-API-DMAC7.html)
RU2014135401A (ru) Производные пиридона
JP2016515560A5 (cg-RX-API-DMAC7.html)
JP2015520143A5 (cg-RX-API-DMAC7.html)
JP2016506960A5 (cg-RX-API-DMAC7.html)